What type of myocardial infarction should be assigned to a patient with myocarditis presenting with chest pain, ST‑segment changes, and elevated troponin?

Type 2 Myocardial Infarction

A patient with myocarditis presenting with chest pain, ST-segment changes, and elevated troponin should be classified as Type 2 myocardial infarction, not Type 1 MI. This distinction is critical because it fundamentally changes management—these patients should NOT receive antiplatelet therapy, anticoagulation, or invasive coronary procedures unless there is clear evidence of obstructive coronary disease.

The Key Distinction

According to the Universal Definition of Myocardial Infarction, the classification hinges on the underlying mechanism 1, 2, 3:

• Type 1 MI: Caused by atherosclerotic plaque rupture, ulceration, fissure, or erosion with resulting intraluminal thrombus leading to decreased myocardial blood flow
• Type 2 MI: Myocardial necrosis where a condition other than coronary plaque instability causes an imbalance between myocardial oxygen supply and demand

Myocarditis explicitly falls under Type 2 MI mechanisms 1, 2. The 2020 ESC Guidelines specifically list myocarditis among conditions causing Type 2 MI, alongside coronary spasm, coronary endothelial dysfunction, tachyarrhythmias, and other non-atherothrombotic causes.

Why This Matters Clinically

The troponin elevation in myocarditis reflects direct inflammatory myocardial injury, not ischemic necrosis from coronary occlusion 4, 5. While both conditions meet the universal definition criteria (elevated troponin + symptoms + ECG changes), the pathophysiology is fundamentally different:

• Myocarditis: Inflammatory injury to cardiomyocytes with troponin release
• Type 1 MI: Ischemic necrosis from thrombotic coronary occlusion

This distinction is not academic—it prevents harmful interventions. The 2022 ACC Expert Consensus explicitly warns that myocardial injury should be classified into chronic myocardial injury, acute myocardial injury, Type 1 MI, and Type 2 MI per the Universal Definition 6.

Diagnostic Approach

When confronted with this presentation, follow this algorithm:

1. Obtain coronary angiography if there is any clinical suspicion for Type 1 MI (especially in patients with cardiac risk factors or age >40)

   • If non-obstructive coronaries are found, this supports myocarditis over Type 1 MI 7, 8

2. Perform cardiac MRI with gadolinium to confirm myocarditis diagnosis 9

   • CMR has 94-100% sensitivity for detecting pericardial/myocardial inflammation
   • Can distinguish myocarditis from MINOCA (myocardial infarction with non-obstructive coronary arteries)
   • Shows characteristic late gadolinium enhancement patterns

3. Consider echocardiography to assess for:

   • Ventricular wall motion abnormalities (may be segmental in myocarditis) 9
   • Pericardial effusion
   • Left ventricular function

4. Check viral serologies if myocarditis is suspected 10

Common Pitfalls to Avoid

Do not reflexively treat as STEMI/NSTEMI based solely on ECG and troponin. Myocarditis can mimic STEMI with ST-elevation, chest pain, and markedly elevated troponins 8, 11, 10. The 2020 ESC Guidelines note that mild troponin elevations (e.g., <2-3 times upper reference limit) in patients with pre-existing cardiac disease do not require Type 1 MI workup unless strongly suggestive clinically 12.

Troponin magnitude alone cannot distinguish causes. Research demonstrates that troponin concentrations at presentation are insufficient to distinguish Type 1 MI from other causes of myocardial injury 13. Even very high troponin levels (>5 times upper reference limit) can occur with myocarditis, not just Type 1 MI 12.

The kinetics matter more than absolute values. Type 1 MI typically shows the highest absolute, relative, and rate of change in troponin, but overlap exists 13. Myocarditis shows typical dynamics with rise and fall distinguishing acute from chronic injury 5.

Treatment Implications

Once classified as Type 2 MI from myocarditis:

• Supportive care is first-line for most patients 4
• Immunosuppression (corticosteroids) is appropriate for eosinophilic or giant cell myocarditis, or myocarditis from systemic autoimmune disorders 4
• Avoid antiplatelet therapy and anticoagulation unless there is concurrent coronary disease
• Approximately 75% have uncomplicated courses with near-zero mortality 4
• Monitor for complications: acute heart failure (19-49% present with dyspnea), ventricular arrhythmias, or hemodynamic instability requiring mechanical support 4, 14

The critical point: classification as Type 2 MI prevents unnecessary and potentially harmful interventions (thrombolytics, dual antiplatelet therapy, invasive procedures) while ensuring appropriate myocarditis-specific management.